Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, ectopic IRF4 expression can augment EBV lytic gene expression induced by anti-immunoglobulin (anti-Ig) or sodium butyrate treatment in all tested lymphoma cells, whereas IRF4 knockout in Raji cells, the only BL cell line with detectable endogenous IRF4 expression, abolishes EBV lytic gene expression induced by anti-Ig, and this is accompanied by the reduction of Blimp-1 expression, whose overexpression, in turn, can rescue EBV lytic gene expression in IRF4 knockout Raji cells.
|
30907723 |
2019 |
Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Burkitt lymphoma in Iraqi children: A distinctive form of sporadic disease with high incidence of EBV<sup>+</sup> cases and more frequent expression of MUM1/IRF4 protein in cases with head and neck presentation.
|
30207048 |
2018 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, comparing MUM1 and MUM1 BL cases of adults (age16 y old and above), the former showed significantly worse prognosis (P=0.041).
|
28079574 |
2017 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pediatric group included Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and MUM1-positive-lymphoma in 7, 3 and 2 cases, respectively.
|
28086220 |
2017 |
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Remarkably, all six primary Burkitt lymphomas with a PCBP1 mutation expressed MUM1/IRF4, which is otherwise detected in around 20-40% of Burkitt lymphomas.
|
26173642 |
2015 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unlike DH-BCL2/MYC lymphomas, however, they are more likely to be CD10(-) but IRF4/MUM-1(+) (P=0.03) and, more like BL, only infrequently express BCL2 (P<0.001), and are cytogenetically less complex (P<0.04).
|
23348205 |
2013 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MUM1 is not an exclusionary diagnostic marker for BL.
|
21740296 |
2011 |
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Distinguishing features from BL included expression of Bcl2 (P<0.0001), Mum1/IRF4 (P=0.006), Ki-67 <95% (P<0.0001), and absence of EBV-EBER (P=0.006).
|
20118770 |
2010 |
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.
|
19144381 |
2009 |
Burkitt Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There were statistically significant differences in the expression of CD10 (28/28 vs 1/16), bcl-2 (3/28 vs 11/16), MUM1 (5/28 vs 15/16), a PI of 95.0% or more (27/28 vs 2/16), and combined CD10+/bcl-2-/bcl-6+ (24/28 vs 1/16) between BLs and DLBCL-HPSSs.
|
17875505 |
2007 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.
|
17651861 |
2007 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTLD expressing the BCL6(+)/MUM1(+/-)/CD138(-) profile reflect B-cells actively experiencing the GC reaction and comprise diffuse large B-cell lymphoma (DLBCL) centroblastic and Burkitt lymphoma.
|
16216037 |
2005 |